NeOnc Technologies Holdings, Inc.NTHI
Oncology16 cited findings · profile updated 2026-08-20
4.63 USDnot live — refreshed daily
About NeOnc Technologies Holdings, Inc.
NeOnc Technologies Holdings, Inc. (NTHI) is focused on oncology. Their drug candidate, NEO100, has been studied in recurrent Grade III or IV Astrocytoma Brain Tumors with IDH1 mutations. In the NEO100-01 Phase 2a trial, NEO100 demonstrated a disease control rate of 66.7% and an objective response rate (ORR) of 8.3%. The primary endpoint for this trial was progression-free survival at six months (PFS6), which was 48.9%. The median overall survival in the NEO100-01 Phase 2a trial was 26.09 months, with overall survival at 6 months at 86.7% and at 12 months at 60.9%. For long-term survivors of NEO100 (cumulative Phase 1 and Phase 2), the median overall survival was 2.2 years.
Compiled from the cited findings below — figures are as stated in each company's published technical reports and filings.
Key figures — cited
| Median overall survival (NEO100-01 Phase 2a) | 26.09 months | NEONC TECHNOLOGIES HOLDINGS, INC. — SEC 8-K (2026-08-13), p.6 |
| PFS6 (NEO100-01 Phase 2a) | 48.9 % | NEONC TECHNOLOGIES HOLDINGS, INC. — SEC 8-K (2026-08-13), p.6 |
| Disease control rate (NEO100-01 Phase 2a) | 66.7 % | NEONC TECHNOLOGIES HOLDINGS, INC. — SEC 8-K (2026-08-13), p.6 |
| Overall survival at 12 months (NEO100-01 Phase 2a) | 60.9 % | NEONC TECHNOLOGIES HOLDINGS, INC. — SEC 8-K (2026-08-13), p.6 |
| Median overall survival of long-term survivors (NEO100 cumulative Phase 1 and Phase 2) | 2.2 years | NEONC TECHNOLOGIES HOLDINGS, INC. — SEC 8-K (2026-08-13), p.6 |
| Objective response rate (ORR) (NEO100-01 Phase 2a) | 8.3 % | NEONC TECHNOLOGIES HOLDINGS, INC. — SEC 8-K (2026-08-13), p.5 |
Key projects
- NEO100 (recurrent Grade III or IV Astrocytoma Brain Tumors with IDH1 mutations)
The NEO100-01 Phase 2a trial for recurrent Grade III or IV Astrocytoma Brain Tumors with IDH1 mutations reported a disease control rate of 66.7%.
- NEO100-02
NEO100-02 is in Phase 2 development.
Every figure cites its source document. Prices refresh daily, not live. Informational only — not investment advice. Explore the Oncology research library →